Terence Philbin, MD
Internal Medicine · Crafton, PANPI 1649233784
Payments from drug & device makers
Across 194 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$735
- Lilly USA, LLC$383
- GSK$351
- Merck$229
- Novo Nordisk$213
- Verona Pharma, Inc.$150
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,352100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $735 |
| Lilly USA, LLC | 22 | $383 |
| GSK | 25 | $351 |
| Merck | 14 | $229 |
| Novo Nordisk | 11 | $213 |
| Verona Pharma, Inc. | 3 | $150 |
| Pfizer | 10 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $127 |
| Paragon 28, Inc. | 1 | $102 |
| Novartis | 6 | $99 |
| Astellas Pharma US Inc | 5 | $93 |
| AstraZeneca | 5 | $76 |
| Abbott | 3 | $62 |
| Boston Scientific | 3 | $62 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Boehringer Ingelheim | 4 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Esperion Therapeutics, Inc. | 3 | $42 |
| Almatica Pharma LLC | 2 | $37 |
| Exact Sciences | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $36 |
| Pulmonx Corporation | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ohtuvayre$108
How this compares
$3,352 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 376 | $314,645 |
| OzempicSemaglutide | 92 | $100,806 |
| XareltoRivaroxaban | 97 | $89,327 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $60,111 |
| TrulicityDulaglutide | 54 | $57,217 |
| JanuviaSitagliptin Phosphate | 55 | $46,997 |
| JardianceEmpagliflozin | 43 | $43,533 |
| EntrestoSacubitril/Valsartan | 47 | $36,743 |
| TradjentaLinagliptin | 31 | $26,674 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $20,293 |
| MounjaroTirzepatide | 17 | $19,189 |
| MyrbetriqMirabegron | 25 | $16,820 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $14,158 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,577 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 51 | $11,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $138 | $314,645376 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix | $351 | $103,302201 claims |
| Novo NordiskOzempic | $213 | $100,80692 claims |
| Johnson & JohnsonXarelto | $15 | $89,32797 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $56 | $81,52196 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $383 | $76,40771 claims |
| MerckJanuvia, Janumet Xr | $229 | $52,96966 claims |
| NovartisEntresto | $99 | $36,74347 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $16,82025 claims |
| AstraZenecaBrilinta | $76 | $8,03713 claims |
| AbbVieSynthroid | $735 | $6,61892 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Crafton
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.